Healthcare provider profile · identity verified

Adolfo Sanchez Ortiz, M.D.

Cardiology · CAYEY, PR · NPI 1821017419

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	2191	376
Amlodipine Besylate	Amlodipine Besylate	1478	276
Metoprolol Succinate	Metoprolol Succinate	1395	239
Rosuvastatin Calcium	Rosuvastatin Calcium	1164	209
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	920	174
Losartan Potassium	Losartan Potassium	872	159
Carvedilol	Carvedilol	847	154
Simvastatin	Simvastatin	827	166
Hydrochlorothiazide	Hydrochlorothiazide	730	139
Candesartan Cilexetil	Candesartan Cilexetil	639	112
Ezetimibe	Ezetimibe	463	84
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	462	82
Furosemide	Furosemide	451	78
Irbesartan	Irbesartan	448	85
Doxazosin Mesylate	Doxazosin Mesylate	444	74
Eliquis	Apixaban	424	70
Clopidogrel	Clopidogrel Bisulfate	383	80
Ramipril	Ramipril	315	44
Xarelto	Rivaroxaban	301	46
Metoprolol Tartrate	Metoprolol Tartrate	295	48
Lisinopril	Lisinopril	260	50
Fenofibrate	Fenofibrate	256	40
Nitroglycerin	Nitroglycerin	252	74
Hydralazine Hcl	Hydralazine Hcl	227	45
Enalapril Maleate	Enalapril Maleate	194	30
Isosorbide Mononitrate Er	Isosorbide Mononitrate	187	34
Farxiga	Dapagliflozin Propanediol	179	34
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	172	34
Spironolactone	Spironolactone	163	29
Brilinta	Ticagrelor	132	26
Atenolol	Atenolol	129	21
Warfarin Sodium	Warfarin Sodium	126	13
Digoxin	Digoxin	107	18
Verapamil Er	Verapamil Hcl	107	15
Indapamide	Indapamide	106	23
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	84	17
Ranolazine Er	Ranolazine	83	13
Valsartan	Valsartan	83	14
Nifedipine Er	Nifedipine	71	13
Bumetanide	Bumetanide	69	suppressed
Amiodarone Hcl	Amiodarone Hcl	67	suppressed
Telmisartan	Telmisartan	66	12
Felodipine Er	Felodipine	65	11
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	63	18
Cilostazol	Cilostazol	55	11
Fenofibric Acid	Fenofibric Acid (Choline)	51	suppressed
Entresto	Sacubitril/Valsartan	50	suppressed
Repatha Syringe	Evolocumab	47	suppressed
Pravastatin Sodium	Pravastatin Sodium	40	suppressed
Jardiance	Empagliflozin	39	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	38	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	37	11
Fenofibrate	Fenofibrate Nanocrystallized	36	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	36	suppressed
Fosinopril Sodium	Fosinopril Sodium	35	suppressed
Nitroglycerin Patch	Nitroglycerin	33	suppressed
Sotalol	Sotalol Hcl	29	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	28	suppressed
Nadolol	Nadolol	26	suppressed
Folic Acid	Folic Acid	22	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	21	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Repatha Sureclick	Evolocumab	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Famotidine	Famotidine	20	suppressed
Pentoxifylline	Pentoxifylline	20	suppressed
Metformin Hcl	Metformin Hcl	17	suppressed
Niacin Er	Niacin	17	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Verapamil Hcl	Verapamil Hcl	15	suppressed
Verapamil Sr	Verapamil Hcl	15	suppressed
Flecainide Acetate	Flecainide Acetate	14	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	13	suppressed
Trandolapril	Trandolapril	13	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Lovastatin	Lovastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error